HMG-CoA reductase and NPC1L1 transporter — Drug Target

All drugs that target HMG-CoA reductase and NPC1L1 transporter — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Statin and ezetimibe combination · Statin and cholesterol absorption inhibitor combination

Marketed (2)

• Rosuvastatin and Ezetimibe · Hanmi Pharmaceutical Company Limited · Statin and ezetimibe combination · Cardiovascular
  Rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.
• simvastatin and ezetimibe · UMC Utrecht · Statin and cholesterol absorption inhibitor combination · Cardiovascular
  Simvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels.